AI summary · may contain errors
In adults with metabolic dysfunction-associated steatohepatitis and F2–F4c fibrosis, zalfermin 30 mg plus semaglutide 2·4 mg did not significantly improve NASH CRN fibrosis by week 52 versus placebo (24% vs 16%).
- Open access
- 9 cites
